pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiska medel - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
bortezomib baxter 3,5 mg pulver till injektionsvätska, lösning
baxter holding b.v. - bortezomib - pulver till injektionsvätska, lösning - 3,5 mg - bortezomib 3,5 mg aktiv substans; mannitol hjälpämne
bleomycin baxter 15000 ie pulver till injektions-/infusionsvätska, lösning
baxter medical ab - bleomycinsulfat - pulver till injektions-/infusionsvätska, lösning - 15000 ie - bleomycinsulfat 15000 ie aktiv substans - bleomycin
fluconazole baxter 2 mg/ml infusionsvätska, lösning
baxter medical ab - flukonazol - infusionsvätska, lösning - 2 mg/ml - flukonazol 2 mg aktiv substans - flukonazol
glucose-na-k baxter 100 mg/ml infusionsvätska, lösning
baxter medical ab - glukosmonohydrat; kaliumklorid; magnesiumkloridhexahydrat; natriumacetattrihydrat; natriumklorid - infusionsvätska, lösning - glukosmonohydrat 110 mg aktiv substans; kaliumklorid 1,5 mg aktiv substans; natriumklorid 1 mg aktiv substans; natriumacetattrihydrat 3,13 mg aktiv substans; magnesiumkloridhexahydrat 0,3 mg aktiv substans - elektrolyter och kolhydrater
desflurane baxter 100 % inhalationsånga, vätska
baxter medical ab - desfluran - inhalationsånga, vätska - 100 % - desfluran 1 ml aktiv substans
glucos baxter viaflo 100 mg/ml infusionsvätska, lösning
baxter medical ab - glukosmonohydrat - infusionsvätska, lösning - 100 mg/ml - glukosmonohydrat 110 g aktiv substans - kolhydrater
glucos baxter viaflo 50 mg/ml infusionsvätska, lösning
baxter medical ab - glukosmonohydrat - infusionsvätska, lösning - 50 mg/ml - glukosmonohydrat 55 mg aktiv substans - kolhydrater
isofluran baxter inhalationsånga, vätska
baxter medical ab - isofluran - inhalationsånga, vätska - isofluran 1 ml aktiv substans - isofluran
mannitol baxter viaflo 150 mg/ml infusionsvätska, lösning
baxter medical ab - mannitol - infusionsvätska, lösning - 150 mg/ml - mannitol 150 mg aktiv substans - mannitol